Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Capricor Therapeutics in a research ...

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR – Get Free Report) have received an average rating of “Buy” from the six ...

Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) shareholders might understandably be very concerned that the share ...

Check the time stamp on this data. Updated AI-Generated Signals for Capricor Therapeutics Inc. (CAPR) available here: CAPR.

The consensus price target hints at a 208.1% upside potential for Capricor (CAPR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings ...

The exosome therapies market is expected to experience significant growth due to increased interest in regenerative medicine, cancer treatments, and drug delivery systems. Leading Indications ...

Capricor stock gains 8% upon completing the rolling submission of the BLA for its lead asset, deramiocel, to treat DMD cardiomyopathy in the United States.

Maxim Group analyst Jason McCarthy maintained a Buy rating on Capricor Therapeutics (CAPR – Research Report) yesterday and set a price target of $25.00. Discover the latest stocks recommended by ...

Ratings for Capricor Therapeutics (NASDAQ:CAPR) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments ...

Capricor Therapeutics (NASDAQ: NASDAQ:CAPR), a biotechnology company specializing in the development of transformative cell and exosome-based therapeutics, has provided an update... Investing.com ...

Cell therapy developer Capricor Therapeutics (NASDAQ:CAPR) announced Thursday the completion of the U.S. marketing application for its lead candidate, deramiocel, for patients with Duchenne ...